ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

STEVE KAPLAN M.D.

2525 E ROOSEVELT ST INTERNAL MEDICINE CLINIC

Phoenix | Arizona | 85008

(602) 344-1119

Incorrect Info?
Search this name in Dollars for Docs »
See this provider's services »

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,400Medicare Part D Prescriptions Filled, Including Refills

Rank: 225 out of 910

$320K Total Retail Price of All Prescriptions

Rank: 361 out of 910

408 Patients Receiving at Least One Drug in Part D
51%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arizona
Lower avg

Schedule Two
Controlled Substances

25% of this provider’s 408 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

8% of this provider’s 408 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

3% of this provider’s 4,503 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arizona
LISINOPRIL 540 393 1 2
SIMVASTATIN 406 283 2 3
HYDROCHLOROTHIAZIDE 400 262 3 12
METFORMIN HCL 330 196 4 6
AMLODIPINE BESYLATE 271 200 5 4
METOPROLOL TARTRATE 237 210 6 7
LEVOTHYROXINE SODIUM 231 121 7 1
LANTUS 191 135 8 30
OXYCODONE-ACETAMINOPHEN 158 79 S2 9 31
OMEPRAZOLE 145 103 10 5
RANITIDINE HCL 132 57 11 28
MORPHINE SULFATE ER 128 59 S2 12 52
FUROSEMIDE 125 96 13 9
ATENOLOL 119 89 14 10
GABAPENTIN 119 61 14 13
AMITRIPTYLINE HCL 118 66 R 16 72
OXYCODONE HCL 117 53 S2 17 42
HYDROCODONE-ACETAMINOPHEN 114 65 S3 18 8
ENDOCET 104 60 S2 19 130
INSULIN SYRINGE 104 80 19 47
PROAIR HFA 103 40 21 40
WARFARIN SODIUM 95 35 22 11
PRAVASTATIN SODIUM 92 65 23 16
GLYBURIDE 90 58 R 24 46
ATORVASTATIN CALCIUM 87 69 25 14
NOVOLOG 81 55 26 78
SERTRALINE HCL 76 43 27 24
ALENDRONATE SODIUM 73 67 28 22
IBUPROFEN 72 25 29 75
TRAZODONE HCL 71 39 30 37
LOSARTAN POTASSIUM 62 47 31 15
NAPROXEN 60 11 32 96
DOXAZOSIN MESYLATE 60 41 32 62
POTASSIUM CHLORIDE 55 41 34 18
PHENYTOIN SODIUM EXTENDED 52 23 35 158
ADVAIR DISKUS 52 30 35 45
FLUTICASONE PROPIONATE 51 21 37 23
JANUVIA 50 28 38 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 28, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.